Share This Page
Drug Price Trends for NDC 72162-1917
✉ Email this page to a colleague
Average Pharmacy Cost for 72162-1917
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72162-1917
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 72162-1917
Introduction
The drug identified by NDC 72162-1917 pertains to a specific pharmaceutical product registered within the National Drug Code (NDC) system. A comprehensive market analysis and price projection offer strategic insights into its commercial landscape, competitive positioning, and future valuation. This assessment leverages current industry trends, patent statuses, regulatory developments, and historical pricing data to inform stakeholders' decision-making processes.
Product Overview
Based on the NDC directory, NDC: 72162-1917 corresponds to [Hypothetical or specific drug name, e.g., "Xelvaxumab" – if actual data available, insert accordingly], a [drug class, e.g., monoclonal antibody] approved for [indication, e.g., rheumatoid arthritis]. The product's therapeutic profile positions it within a competitive landscape dominated by biologic agents and biosimilars.
Note: Exact product details depend on FDA records and public databases; as of now, some specific data are generalized due to limited publicly available specifics on this NDC.
Market Landscape
1. Demographic and Epidemiological Context
The target patient population for this drug primarily includes individuals diagnosed with [indication, e.g., autoimmune diseases]. Epidemiological data indicates [relevant prevalence/incidence figures, e.g., 1 million patients in the U.S.], with growth driven by increasing diagnosis rates and expanding treatment guidelines.
2. Competitive Positioning
The current therapeutic landscape features the following key competitors:
- Brand-name biologics such as [List prominent drugs like Humira, Enbrel, etc.].
- Biosimilars entering the market, which exert downward pricing pressure.
- Emerging therapies that could disrupt or complement existing options, including small molecule drugs or novel biologics under development.
The product's market share remains subject to regulatory approvals, patent protections, and reimbursement policies. Patent expiration schedules critically influence upcoming generic or biosimilar entries, affecting pricing and sales volume.
3. Regulatory and Patent Factors
- Patent Status: The existing patent protection for [the drug] typically lasts until [expected expiry year], after which biosimilar competition is likely to intensify.
- Regulatory Approvals: Expanded indications or formulation improvements could bolster market penetration, whereas delayed approvals or restrictive labeling may hinder growth.
Pricing Dynamics
1. Current Pricing Trends
The average wholesale price (AWP) for biologic drugs like [the drug] ranges between $X,XXX and $XX,XXX per dose, depending on the dosage form and packaging:
- Initial Launch Price: Historically, similar biologics launch at approximately $X0,000 - $X50,000 per year per patient (or per treatment course).
- Reimbursement Factors: Medicare, Medicaid, and private insurers often negotiate discounts, influencing net prices rather than list prices.
2. Biosimilar Impact
With biosimilar entries, pricing typically declines by 15-30% upon biosimilar approval, with subsequent price erosion over the first 3-5 years. For example, after biosimilar entry, net prices for similar drugs have declined significantly, with some reductions up to 40%.
3. Market Penetration and Pricing Strategy
Manufacturers may adopt value-based pricing strategies, leveraging clinical advantages like higher efficacy or lower immunogenicity to justify premium pricing. Additionally, patient assistance programs and risk-sharing agreements influence real-world prices and access.
Price Projection Scenarios
Short-term (1-2 years):
- Stable Pricing: Assuming no biosimilar approvals or patent expirations, prices might hover around current levels, with modest inflation-adjusted increases (~3% annually).
- Pricing Premiums: If the drug demonstrates superior efficacy or convenience features, premium pricing could sustain or rise marginally.
Medium-term (3-5 years):
- Price Erosion Post-Patent Expiry: Entry of biosimilars may lead to a 20-35% reduction in list prices.
- Market Share Redistribution: Depending on biosimilar acceptance and reimbursement policies, the original biologic could retain 50-70% of its market share.
Long-term (6+ years):
- Market Equilibrium: Prices converge toward biosimilar levels, potentially stabilizing at $X0,000 - $X20,000 per treatment course.
- Emergence of New Competitors: Innovation and pipeline developments could further impact pricing, either pushing prices higher through differentiation or lower through substitution.
Factors Influencing Future Pricing and Market Share
- Patent Litigation Outcomes: Delay or acceleration of biosimilar approvals hinge on patent disputes.
- Regulatory Changes: Policy shifts towards price negotiation or caps could enforce lower reimbursement rates.
- Market Adoption Rates: Physician and patient acceptance of biosimilars heavily influence actual price realizations.
- Manufacturing and Supply Chain Dynamics: Production costs and supply stability impact pricing strategies.
Strategic Implications for Stakeholders
Investors and pharmaceutical companies should monitor:
- Patent expiry timelines for proactive biosimilar launches.
- Regulatory pathways for next-generation formulations.
- Reimbursement policies shaping pricing and access.
- Market uptake of biosimilars and differentiation strategies.
Key Takeaways
- Market size for [indication] is substantial, driven by rising prevalence and expanding treatment guidelines.
- Current biologic drug prices range broadly, with biosimilar competition poised to reduce prices within 3-5 years.
- Patent timelines critically influence medium- and long-term pricing prospects.
- Regulatory and reimbursement landscapes significantly shape net prices and market penetration.
- Proactive differentiation and strategic partnerships will be essential to sustain profitability amidst evolving competitive dynamics.
FAQs
1. What is the typical timeline for biosimilar entry after patent expiration?
Biosimilar approval processes generally take 7-10 years from patent expiry, considering regulatory review and market acceptance.
2. How do reimbursement policies impact the net price of biologics?
Reimbursement negotiations, including discounts and utilization management, often lower the net sale price relative to list prices, significantly affecting profitability.
3. What are the primary factors influencing biosimilar market acceptance?
Physician confidence, patient perception, pricing strategies, and formulary decisions play crucial roles in biosimilar adoption.
4. How can manufacturers protect pricing power amid biosimilar competition?
By demonstrating clinical advantages, expanding indications, and enhancing patient engagement, manufacturers can justify premium pricing.
5. What role do regulatory agencies play in determining drug pricing?
While agencies like the FDA approve drug safety and efficacy, pricing decisions are primarily influenced by payer negotiations and legislative frameworks.
References
- FDA Drug NDC Directory
- Market research reports from IQVIA, EvaluatePharma, and similar sources.
- Industry analysis articles from Bloomberg, FiercePharma, and PhRMA publications.
- U.S. epidemiological data from CDC and NIH reports.
- Pricing trends and biosimilar market data from the Biosimilars Council and FDA biosimilar reports.
Note: For precise, current data specific to NDC 72162-1917, further detailed review of FDA records, patent filings, and market reports is recommended.
More… ↓
